# Cholinesterase Inhibitors to Slow Progression of Visual Hallucinations in Parkinson&Apos;s Disease

> **NCT01856738** · PHASE4 · TERMINATED · sponsor: **Amsterdam UMC, location VUmc** · enrollment: 91 (actual)

## Conditions studied

- Parkinson's Disease

## Interventions

- **DRUG:** Rivastigmine
- **DRUG:** Placebo (for rivastigmine)

## Key facts

- **NCT ID:** NCT01856738
- **Lead sponsor:** Amsterdam UMC, location VUmc
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-11
- **Primary completion:** 2018-09
- **Final completion:** 2018-09
- **Target enrollment:** 91 (ACTUAL)
- **Why stopped:** enrollment to slow, insufficient funds
- **Last updated:** 2018-10-09

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01856738

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01856738, "Cholinesterase Inhibitors to Slow Progression of Visual Hallucinations in Parkinson&Apos;s Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01856738. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*